JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Suletud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad
By Trading Economics
Sissetulek	63M 55M
Müük	32M 104M
P/E Sektori keskmine	10.856 60.328
Aktsiakasum	0.24
Kasumimarginaal	52.807
Töötajad	65
EBITDA	63M 58M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-8.2M 184M
Eelmine avamishind	0
Eelmine sulgemishind	0

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2026, 00:00 UTC

Tulu

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24. apr 2026, 00:00 UTC

Tulu

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23. apr 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23. apr 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. apr 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

23. apr 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23. apr 2026, 23:13 UTC

Omandamised, ülevõtmised, äriostud

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23. apr 2026, 22:33 UTC

Tulu

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23. apr 2026, 22:17 UTC

Tulu

PLS Executed Offtake Agreement With Ronbay

23. apr 2026, 22:17 UTC

Tulu

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23. apr 2026, 22:16 UTC

Tulu

PLS Commences Commissioning of Midstream Demonstration Plant

23. apr 2026, 22:15 UTC

Tulu

PLS Group Reaffirms FY26 Guidance for All Metrics

23. apr 2026, 22:14 UTC

Tulu

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23. apr 2026, 22:14 UTC

Tulu

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23. apr 2026, 22:13 UTC

Tulu

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23. apr 2026, 22:12 UTC

Tulu

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23. apr 2026, 22:12 UTC

Tulu

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23. apr 2026, 22:11 UTC

Tulu

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23. apr 2026, 22:10 UTC

Tulu

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23. apr 2026, 22:09 UTC

Tulu

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23. apr 2026, 22:08 UTC

Tulu

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23. apr 2026, 22:04 UTC

Tulu

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23. apr 2026, 21:56 UTC

Market Talk

Tulu

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23. apr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23. apr 2026, 21:27 UTC

Tulu

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23. apr 2026, 21:25 UTC

Tulu

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23. apr 2026, 21:24 UTC

Tulu

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23. apr 2026, 21:24 UTC

Tulu

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23. apr 2026, 21:21 UTC

Tulu

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23. apr 2026, 21:21 UTC

Tulu

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.